Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Deloitte
Baxter
Farmers Insurance
Mallinckrodt
Moodys
Cipla
UBS
Chubb
Harvard Business School

Generated: October 23, 2017

DrugPatentWatch Database Preview

PEPCID RPD Drug Profile

« Back to Dashboard

What is the patent landscape for Pepcid Rpd, and when can generic versions of Pepcid Rpd launch?

Pepcid Rpd is a drug marketed by Merck and is included in one NDA.

The generic ingredient in PEPCID RPD is famotidine. There are eighteen drug master file entries for this compound. One hundred and twenty-four suppliers are listed for this compound. Additional details are available on the famotidine profile page.

Summary for Tradename: PEPCID RPD

US Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list67
Clinical Trials: see list13
Patent Applications: see list5,281
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PEPCID RPD at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
PEPCID RPD
famotidine
TABLET, ORALLY DISINTEGRATING;ORAL020752-001May 28, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
Merck
PEPCID RPD
famotidine
TABLET, ORALLY DISINTEGRATING;ORAL020752-002May 28, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PEPCID RPD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
PEPCID RPD
famotidine
TABLET, ORALLY DISINTEGRATING;ORAL020752-001May 28, 1998► Subscribe► Subscribe
Merck
PEPCID RPD
famotidine
TABLET, ORALLY DISINTEGRATING;ORAL020752-002May 28, 1998► Subscribe► Subscribe
Merck
PEPCID RPD
famotidine
TABLET, ORALLY DISINTEGRATING;ORAL020752-001May 28, 1998► Subscribe► Subscribe
Merck
PEPCID RPD
famotidine
TABLET, ORALLY DISINTEGRATING;ORAL020752-002May 28, 1998► Subscribe► Subscribe
Merck
PEPCID RPD
famotidine
TABLET, ORALLY DISINTEGRATING;ORAL020752-001May 28, 1998► Subscribe► Subscribe
Merck
PEPCID RPD
famotidine
TABLET, ORALLY DISINTEGRATING;ORAL020752-002May 28, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Accenture
McKesson
Medtronic
Federal Trade Commission
Colorcon
McKinsey
Queensland Health
US Army
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot